Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

Brain Research

Volumn 783, Issue 1, 1998, Pages 109-114

  Beal, M Flint ^a   Matthews, Russell T ^a   Tieleman, Alide ^b,c   Shults, Clifford W ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Neurology Service   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coenzyme Q10; Dopamine; Mitochondria; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; UBIDECARENONE; DOPAMINE; DRUG DERIVATIVE; UBIQUINONE;

AGING; ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LOCALIZATION; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMISTRY; MALE; METABOLISM; NERVE FIBER; ORAL DRUG ADMINISTRATION; PATHOLOGY; SUBSTANTIA NIGRA; ULTRASTRUCTURE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, ORAL; AGING; ANIMALS; AXONS; CORPUS STRIATUM; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; SUBSTANTIA NIGRA; UBIQUINONE;

EID: 0031594295     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01192-X     Document Type: Article

References (35)

1. Akaneya Y., Takahashi M., Hatanaka H. Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. 193:1995;53-56.
2. Beal M.F., Matson W.R., Swartz K.J., Gamache P.H., Bird E.D. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 55:1990;1327-1339.
3. Benecke R., Strümper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 116:1993;1451-1463.
4. Chiueh C.C., Krishna G., Tulsi P., Obata T., Lang K., Huang S.-J., Murphy D.L. Intracranial microdialysis of salicyclic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: Effects of MPP+. Free Radic. Biol. Med. 13:1992;581-583.
5. Date I., Felten D.L., Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519:1990;266-276.
6. Deutch A.Y., Goldstein M., Baldino F., Roth R.H. Telencephalic projections of the A8 dopamine cell group. Ann. NY Acad. Sci. 537:1988;27-50.
7. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta. 1271:1995;195-204.
8. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
9. W.R.G. Gibb, Neuropathology of Parkinson's disease and related disorders, in: J.M. Cedarbaum, S.T. Gancher (Eds.), Parkinson's Disease - Neurologic Clinics, Saunders, Philadelphia, 1992, pp. 567-593.
10. Haas R., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial Complex I and Complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722.
11. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195:1980;123-137.
12. Herkenhan M., Little M.D., Bankiewicz K., Yang S.-c., Markey S.P., Johannssen J.N. Selective retention of MPP+ within the monaminergic systems in the primate brain following MPTP administration: and in vivo autoradiographic study. Neuroscience. 40:1991;133-158.
13. Janetzky B., Hauck S., Youdim M.B.H., Riederer P., Jellinger K., Pantucek F., Zöchling R., Boissl K.W., Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169:1994;126-128.
14. Jenner P., Schapira A.H.V., Marsden C.D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
15. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H.V. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788.
16. Kurlan R., Kim M.H., Gash D.M. The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann. Neurol. 29:1991;677-679.
17. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a produce of meperidine-analog synthesis. Science. 219:1983;979-980.
18. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-443.
19. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
20. 10 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55:1990;2142-2145.
21. Schapira A.H.V. Oxidative stress in Parkinson's disease. Neuropathol. Appl. Neurobiol. 21:1995;3-9.
22. Schnieder H., Lemasters J.J., Hackenbrock C.R. Lateral diffusion of ubiquinone during electron transfer in phospholipid- and ubiquinone-enriched mitochondrial membranes. J. Biol. Chem. 257:1982;10789-10793.
23. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132:1995;279-283.
24. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigra-striatal projection by MPTP. Brain Res. 527:1990;7-20.
25. Shults C.W., Nasirian F., Ward D.M., Nakano K., Pay M., Hill L.R., Haas R.H. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology. 45:1995;344-348.
26. Shults C.W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport. 7:1996;627-631.
27. 10 Levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42:1997;261-264.
28. Singer T.P., Castagnoli N. Jr., Ramsay R.R., Trevor A.J. Biochemical events in the development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49:1987;1-8.
29. Söderberg M., Edlund C., Kristensson K., Dallner G. Lipid compositions of different regions of the human brain during aging. J. Neurochem. 54:1992;415-423.
30. Sriaram K., Pai K.S., Boyd M.R., Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749:1997;44-52.
31. Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc. Natl. Acad. Sci. USA. 88:1991;1646-1650.
32. 10 in aged rat skeletal muscle. Biochem. Mol. Biol. Int. 37:1995;1110-1120.
33. Voorn P., Kalsbeek A., Jorritsma-Byham B., Groenewegen H.J. The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the rat. Neuroscience. 25:1988;857-887.
34. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural. Transm. 4:1992;27-34.
35. Zuddas A., Corsini G.U., Schinelli S., Johannessen J.N., di Porzio U., Kopin I.J. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res. 501:1989;1-10.